Targeting Right Ventricle in Pulmonary Hypertension Gilead

Phase 4 Completed 22 enrolled University of Pennsylvania Brigham and Women's Hospital · collab Gilead Sciences · collab University of Maryland · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is looking to see if giving ranolazine to subjects on stable pulmonary hypertension therapies but with right ventricular dysfunction (RVEF \<45%) will improve their health by improving right ventricular (RV) function.

Timeline

Start: 2016-07
Primary completion: 2017-12
Completion: 2018-01

Publications

Han Y, Forfia PR, Vaidya A, Mazurek JA, Park MH, Ramani G, Chan SY, Waxman AB. Rationale and design of the ranolazine PH-RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension. Open Heart. 2018 Feb 23;5(1):e000736. doi: 10.1136/openhrt-2017-000736. eCollection 2018.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ranolazine	Small molecule	1000 mg	Oral

Targeting Right Ventricle in Pulmonary Hypertension Gilead

Summary

Timeline

Publications

Drugs

Indications